MEN1611, a PI3K inhibitor, combined with trastuzumab +/- fulvestrant for HER2+/PIK3CA mutant advanced or metastatic breast cancer: updated safety and efficacy results from the ongoing phase 1b study (B-PRECISE-01)Martine Piccart,Audrey Hennequin,Manuel Ruiz Borrego,Santiago Escriva-De-Romani,Anja Williams,Begona Jimenez Rodriguez,Gianluca Del Conte,Sacha J. Howell,Michela Palleschi,Matteo Simonelli,Francois P. Duhoux,Diego Tosi,Bernard Doger De Speville Uribe,Yolanda Jerez Gilarranz, Pierfrancesco Tassone,Giuseppe Curigliano,Simon Waters,Philippe Aftimos,Hans Wildiers,Simona Scartoni,Bartomeu Piza Vallespir,Ram Charan Shankaraiah,Krzysztof Grzegorzewski,Nassir HabboubiCANCER RESEARCH（2023）引用 0|浏览27暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
